Search Results 1691-1700 of 2818 for 씨밀레토토

  1. Manufacturing Outcomes with Patient Factors from Multiple Myeloma Patients Prescribed Ciltacabtagene Autoleucel - Mayo Clinic

    The purpose of this study is to identify patient factors that are associated with low-viability or low-dose out-of specification (OOS) in ciltacabtagene ...

  2. Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) - Mayo Clinic

    The primary purpose of this study is to assess the effects of a daily single oral dose of 20 mg tasimelteon compared to placebo on Sleep Onset (change from ...

  3. COVID-19 (Coronavirus) Pandemic on Health and Healthcare - Mayo Clinic

    The purpose of this study is to identify correlates of healthcare-seeking behavior in patients with ACS and CHF and its association with psychosocial and health ...

  4. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

    Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known ...

  5. Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors - Mayo Clinic

    Radiological tumor assessments will be performed at defined time points until the patient's disease progresses. Blood samples will be collected for safety, ...

  6. Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papillomavirus-Related Cancer in Adult Women After Kidney Transplant - Mayo Clinic

    About this study. This trial studies whether the nonavalent human papillomavirus vaccine given to adult women prior to kidney transplantation can help the ...

  7. Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer - Mayo Clinic

    SC-003 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. Participation eligibility. Participant ...

  8. Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) - Mayo Clinic

    During an initial Dose Evaluation phase (first 2 cycles) to determine Dose Limiting Toxicities (DLTs), dose combinations of pembrolizumab 200 mg followed by ...

  9. Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer - Mayo Clinic

    This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal ...

  10. Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients with Advanced Cancers - Mayo Clinic

    This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or ...